Safety, Tolerability and Pharmacokinetics of TPOXX When Administered Orally for 28 Days
- First Posted Date
- 2021-07-21
- Last Posted Date
- 2024-10-23
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 467
- Registration Number
- NCT04971109
- Locations
- 🇺🇸
Midwest Clinical Research Center, Dayton, Ohio, United States
🇺🇸Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸Meridian Clinical Research, Omaha, Nebraska, United States
Study to Assess the Safety and Pharmacokinetics of TPOXX® When Administered Orally for 28 Days With JYNNEOS
- Conditions
- Interventions
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 100
- Registration Number
- NCT04957485
- Locations
- 🇺🇸
Meridian Clinical Research, Omaha, Nebraska, United States
🇺🇸Aventiv Research Inc, Columbus, Ohio, United States
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 44
- Registration Number
- NCT04485039
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
Safety, Tolerability and PK of TPOXX in Adults Weighing More Than 120 KG
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2020-05-21
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 34
- Registration Number
- NCT04392739
- Locations
- 🇺🇸
PPD Phase I Clinic, Austin, Texas, United States
A Phase 4, Observational Field Study to Evaluate TPOXX in Patients With Smallpox
- Conditions
- First Posted Date
- 2019-06-03
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- SIGA Technologies
- Registration Number
- NCT03972111
- Locations
- 🇺🇸
Investigator Site, Corvallis, Oregon, United States
A Trial to Assess the Safety, Tolerability, and Pharmacokinetics of the Anti-Orthopoxvirus Compound Tecovirimat
- First Posted Date
- 2015-06-18
- Last Posted Date
- 2017-11-28
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 449
- Registration Number
- NCT02474589
- Locations
- 🇺🇸
Paradigm Research, San Diego, California, United States
🇺🇸Sundance Clinical Research LLC, Saint Louis, Missouri, United States
🇺🇸Center for Pharmaceutical Research, Kansas City, Missouri, United States
Safety, Tolerability, Pharmacokinetics (PK) of the Anti-Orthopox Drug, ST-246
- Conditions
- Interventions
- First Posted Date
- 2009-05-25
- Last Posted Date
- 2010-09-21
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 107
- Registration Number
- NCT00907803
- Locations
- 🇺🇸
Hawaii Clinical Research Center, Honolulu, Hawaii, United States
🇺🇸Apex Research Institute, Santa Ana, California, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
Phase I Trial of an Investigational Small Pox Medication
- Conditions
- Interventions
- First Posted Date
- 2008-08-06
- Last Posted Date
- 2015-06-29
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 12
- Registration Number
- NCT00728689
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Phase I, Escalating, Multiple-Dose, ST-246 Safety, Tolerability and Pharmacokinetics 21-Day Trial in Healthy Volunteers
- First Posted Date
- 2007-02-06
- Last Posted Date
- 2017-07-27
- Lead Sponsor
- SIGA Technologies
- Target Recruit Count
- 30
- Registration Number
- NCT00431951
- Locations
- 🇺🇸
Orlando Clinical Research, Orlando, Florida, United States